BRPI0411901A - micropartìculas - Google Patents

micropartìculas

Info

Publication number
BRPI0411901A
BRPI0411901A BRPI0411901-0A BRPI0411901A BRPI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A BR PI0411901 A BRPI0411901 A BR PI0411901A
Authority
BR
Brazil
Prior art keywords
microparticles
oxycodone
plasticizer
extruding
lubricant
Prior art date
Application number
BRPI0411901-0A
Other languages
English (en)
Inventor
Malcolm Walden
Geoffrey Gerard Hayes
Hassan Mohammad
Harjit Tamber
Steve Whitelock
Vincenzo Martinelli
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33556051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411901(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0315137A external-priority patent/GB0315137D0/en
Priority claimed from GB0403102A external-priority patent/GB0403102D0/en
Priority claimed from GB0413454A external-priority patent/GB0413454D0/en
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of BRPI0411901A publication Critical patent/BRPI0411901A/pt
Publication of BRPI0411901B1 publication Critical patent/BRPI0411901B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Manufacturing Of Micro-Capsules (AREA)

Abstract

"MICROPARTìCULAS". A presente invenção refere-se a múltiplas micropartículas de oxicodona, as quais podem ser produzidas mediante extrusão de uma mistura que, de forma adequada, contém: (a) oxicodona; (b) copolímero de metacrilato de amónio insolúvel em água; (c) plastificante; (d) lubrificante; e (e) agente modificador de permeabilidade à água.
BRPI0411901-0A 2003-06-27 2004-06-23 Multiparticulados extrudados de material fundido de liberação controlada, seu processo de preparação e composição farmacêutica na forma de dose unitária BRPI0411901B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0315137A GB0315137D0 (en) 2003-06-27 2003-06-27 Multiparticulates
GB0315137.0 2003-06-27
GB0403102A GB0403102D0 (en) 2004-02-12 2004-02-12 Multiparticulates
GB0403102.7 2004-02-12
GB0413454.0 2004-06-16
GB0413454A GB0413454D0 (en) 2004-06-16 2004-06-16 Multiparticulates
PCT/GB2004/002705 WO2005000310A1 (en) 2003-06-27 2004-06-23 Multiparticulates

Publications (2)

Publication Number Publication Date
BRPI0411901A true BRPI0411901A (pt) 2006-08-08
BRPI0411901B1 BRPI0411901B1 (pt) 2019-04-02

Family

ID=33556051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411901-0A BRPI0411901B1 (pt) 2003-06-27 2004-06-23 Multiparticulados extrudados de material fundido de liberação controlada, seu processo de preparação e composição farmacêutica na forma de dose unitária

Country Status (25)

Country Link
EP (2) EP1889621B1 (pt)
JP (2) JP5348841B2 (pt)
KR (1) KR101116518B1 (pt)
AR (1) AR044935A1 (pt)
AT (1) ATE453394T1 (pt)
AU (1) AU2004251481B2 (pt)
BR (1) BRPI0411901B1 (pt)
CA (1) CA2530385C (pt)
CY (2) CY1109917T1 (pt)
DE (1) DE602004024888D1 (pt)
DK (2) DK1889621T3 (pt)
EA (1) EA013424B1 (pt)
ES (2) ES2490598T3 (pt)
HR (2) HRP20100127T1 (pt)
IL (1) IL172730A (pt)
MX (1) MXPA05013799A (pt)
MY (1) MY176831A (pt)
NO (1) NO20060443L (pt)
NZ (1) NZ544181A (pt)
PE (1) PE20050286A1 (pt)
PL (2) PL1644002T3 (pt)
PT (2) PT1889621E (pt)
SI (2) SI1644002T1 (pt)
TW (1) TWI357815B (pt)
WO (1) WO2005000310A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2266564E (pt) 1997-12-22 2013-06-20 Euro Celtique Sa Forma de dosagem farmacêutica por via oral compreendendo uma combinação de um agonista opióide e de um antagonista opióide
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
WO2002092060A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
PT2425821T (pt) 2002-04-05 2017-08-23 Mundipharma Farmacêutica Lda Preparação farmacêutica contendo oxicodona e naloxona
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
GB2418854B (en) * 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007085024A2 (en) * 2006-01-21 2007-07-26 Abbott Gmbh & Co. Kg Dosage form and method for the delivery of drugs of abuse
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
ES2350029T3 (es) * 2007-03-02 2011-01-17 Farnam Companies, Inc. Pellets de liberación sostenida que comprenden un material tipo cera.
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CA2702904A1 (en) 2007-10-19 2009-04-23 Otsuka Pharmaceutical Co., Ltd. Matrix-type pharmaceutical solid preparation
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
ES2586439T3 (es) * 2008-09-18 2016-10-14 Purdue Pharma Lp Formas farmacéuticas de dosificación que comprenden poli (E-caprolactona)
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
ES2706407T3 (es) 2009-03-10 2019-03-28 Euro Celtique Sa Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
EP2534479A1 (en) * 2010-02-11 2012-12-19 Harry Leider Methods of normalizing measured drug concentrations and testing for non-compliance with a drug treatment regimen
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
NZ716267A (en) 2013-07-23 2017-05-26 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861598A (en) * 1986-07-18 1989-08-29 Euroceltique, S.A. Controlled release bases for pharmaceuticals
AU660290B2 (en) * 1990-08-09 1995-06-22 Endocon, Inc. Multiple drug delivery system
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
MX9603480A (es) * 1994-02-16 1997-12-31 Abbott Lab Procedimiento para preparar formulaciones farmaceuticas en particulas finas.
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE69625822T2 (de) * 1995-05-01 2003-06-05 Samyang Corp Implantierbare, bioresorbierbare membran und verfahren zu ihrer herstellung
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
AU3404997A (en) * 1996-05-31 1998-01-05 Euro-Celtique S.A. Sustained release oxycodone formulations with no fed/fast effect
US6022554A (en) * 1997-12-15 2000-02-08 American Home Products Corporation Polymeric microporous film coated subcutaneous implant
IT1304152B1 (it) * 1998-12-10 2001-03-08 Mediolanum Farmaceutici Srl Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
FR2795326B1 (fr) * 1999-06-28 2001-08-31 Adir Composition pharmaceutique solide thermoformable a liberation controlee
KR20020059653A (ko) * 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
BRPI0108380B8 (pt) * 2000-02-08 2021-05-25 Euro Celtique S/A fórmulas de opióides agonistas resistentes à adulteração, método para diminuir o abuso de um opióide agonista numa fórmula de dosagem oral, método de preparação de uma fórmula de dosagem oral e método de tratamento da dor
FR2818552B1 (fr) * 2000-12-26 2003-02-07 Servier Lab Compositions pharmaceutique solide thermoformable pour la liberation controlee d'ivabradine
CN1658836A (zh) * 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
WO2004066983A2 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Controlled release of highly soluble agents
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates

Also Published As

Publication number Publication date
NO20060443L (no) 2006-01-27
NZ544181A (en) 2008-12-24
NO333779B1 (pt) 2013-09-16
MXPA05013799A (es) 2006-03-13
EP1889621A1 (en) 2008-02-20
EP1644002B1 (en) 2009-12-30
TW200510000A (en) 2005-03-16
EP1889621B1 (en) 2014-05-21
TWI357815B (en) 2012-02-11
PT1889621E (pt) 2014-08-27
CA2530385C (en) 2013-05-28
KR101116518B1 (ko) 2012-03-13
PL1889621T3 (pl) 2014-10-31
ES2337468T3 (es) 2010-04-26
IL172730A0 (en) 2006-04-10
JP5960089B2 (ja) 2016-08-02
PE20050286A1 (es) 2005-06-13
MY176831A (en) 2020-08-24
PT1644002E (pt) 2010-03-03
DK1889621T3 (da) 2014-08-11
AR044935A1 (es) 2005-10-12
ATE453394T1 (de) 2010-01-15
CY1115415T1 (el) 2017-01-04
HRP20140635T1 (hr) 2014-09-26
EP1644002A1 (en) 2006-04-12
HRP20100127T1 (hr) 2010-04-30
PL1644002T3 (pl) 2010-05-31
ES2490598T3 (es) 2014-09-04
SI1889621T1 (sl) 2014-09-30
SI1644002T1 (sl) 2010-03-31
JP2007520429A (ja) 2007-07-26
EA013424B1 (ru) 2010-04-30
JP2013209387A (ja) 2013-10-10
WO2005000310A1 (en) 2005-01-06
IL172730A (en) 2010-12-30
DE602004024888D1 (de) 2010-02-11
BRPI0411901B1 (pt) 2019-04-02
AU2004251481B2 (en) 2010-01-28
JP5348841B2 (ja) 2013-11-20
DK1644002T3 (da) 2010-04-19
EA200600111A1 (ru) 2006-06-30
CA2530385A1 (en) 2005-01-06
AU2004251481A1 (en) 2005-01-06
CY1109917T1 (el) 2014-09-10
KR20060026892A (ko) 2006-03-24

Similar Documents

Publication Publication Date Title
BRPI0411901A (pt) micropartìculas
BR0313549A (pt) Composições de poliolefina plastificadas
BRPI0512582A (pt) plastisóis à base de um polìmero misto de metacrilato de metila
BRPI0508758A (pt) processo para a preparação de cloridrato de oxicodona tendo menos que 25 ppm de 14 - hidroxicodeinona
AR054233A1 (es) Composiciones de anticuerpos igg2
BRPI0606145C1 (pt) formas farmacêuticas sólidas de cloridrato de oxicodona resistentes ao rompimento com liberação sustentada
DE602004014462D1 (de) Wässrige Dispersionen, enthaltend fluorierte Polymere
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
DE60335716D1 (de) Beschleuniger-zusammensetzung
DE602004006169D1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro-äcycloalkylaminü-pyrimidoä1,2aüpyrimidin-6-onderivate
DE60334379D1 (de) Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung
BRPI0405450A (pt) Agente de revestimento
DE60326373D1 (de) Gaspedal
DE50312717D1 (de) Kraftfahrzeugbaugruppe
DE50310143D1 (de) Fahrpedal
BRPI0501602A (pt) Componente composto
BRPI0313645A2 (pt) composições de inalação com relações de droga elevadas.
GT200400183A (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
ATE316104T1 (de) Kationische kern/schale-teilchen mit säure- quellbaren schalen
ATE424438T1 (de) Wässrige bimodale kunststoffdispersionen
UY28390A1 (es) Multiparticulados
BR0204238B1 (pt) pregador de objetos.
BR8302102U (pt) Disposição aplicada em equipamento para fisicultura, com injeção plástica
BRPI0405427A (pt) Correia v multirraiada de altura de raia reduzida
RU2000116332A (ru) Антгельминтное средство

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07B Technical examination (opinion): publication cancelled [chapter 7.2 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25G Requested change of headquarter approved

Owner name: EURO-CELTIQUE S.A (LU)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2594 DE 24-09-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.